Samatasvir

Samatasvir is an experimental drug that was under development for the treatment of Hepatitis C. It is a direct-acting antiviral agent (DAA) and was being developed by Bristol-Myers Squibb.

History

Samatasvir was first identified as a potential treatment for Hepatitis C in the early 2010s. It was part of a new wave of DAAs that were being developed to improve upon the existing treatments for Hepatitis C, which often had severe side effects and were not always effective.

Mechanism of Action

Samatasvir is a NS5A inhibitor. The NS5A protein is essential for the replication of the Hepatitis C virus, and by inhibiting this protein, Samatasvir prevents the virus from replicating. This reduces the amount of virus in the body, which can help to alleviate the symptoms of Hepatitis C and potentially lead to a cure.

Clinical Trials

Several clinical trials were conducted to test the safety and efficacy of Samatasvir. These trials found that Samatasvir was generally well-tolerated and had a high cure rate when used in combination with other antiviral drugs. However, development of the drug was eventually discontinued for reasons that were not publicly disclosed.

See Also

• Hepatitis C
• Direct-acting antiviral agent
• NS5A inhibitor
• Bristol-Myers Squibb

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian